Brief: Arrivent Announces Ind Clearance For Novel Tetravalent Muc16/Napi2b Targeting Adc Arr-002 With Initial Focus In Ovarian And Endometrial Cancers
07/05/2026 13:05
May 7 (Reuters) - Arrivent Biopharma Inc AVBP.O: ARRIVENT ANNOUNCES IND CLEARANCE FOR NOVEL TETRAVALENT MUC16/NAPI2B TARGETING ADC ARR-002 WITH INITIAL FOCUS IN OVARIAN AND ENDOMETRIAL CANCERS ARRIVENT BIOPHARMA INC - PHASE 1 INITIATION FOR ARR-002 EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNX4ND38k Further company coverage: AVBP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ArriVent BioPharma
See all newsBrief: Arrivent Announces First Patient Dosed With Novel Tetravalent Muc16/Napi2b Dual Target Adc, Arr-002
US RESEARCH ROUNDUP-Allstate, Caribou Biosciences, Zscaler
U.S. STOCKS ON THE MOVE-Becton Dickinson, Constellation Energy, Marvell
U.S. STOCKS ON THE MOVE-Constellation Energy, AMD
ArriVent falls after lung cancer drug misses late-stage trial goal